Everolimus Impedes Disease Progression for Kidney Cancer Patients

Patients suffering from advanced kidney diseases now have longer chance for better condition as anti-cancer drug everolimus slows down its progression and further prevents the disease from spreading. This was the findings of the ECC2013 or the 2013 European Congress. According to Dr. Bernard Escudier, the chairman of Genitourinary Tumour Board, the results revealed that 59% of the respondents who were given everolimus treatment remained stable and were not subject to worsened conditions.

“Advanced papillary cancer is a very difficult cancer to treat, and because there is no standard care, there is disagreement amongst expert regarding the best treatment for these patients,” Escudier added. He said the clinical findings suggest that the drug everolimus can represent a new option for cancer treatment. Everolimus is known as mTOR or mammalian target of rapamycin inhibitor. It is a protein known to regulate the processes that involved cell growth like proliferation and cell metabolism.